[Controlled evaluation of a new synthetic spasmolytic (DA 3177) in/pathology of the digestive system].
D000328:Adult; D000368:Aged; D001565:Benzoates / Q000627:therapeutic use*; D002764:Cholecystitis / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003092:Colitis / Q000188:drug therapy; D004382:Duodenitis / Q000188:drug therapy; D005260:Female; D005756:Gastritis / Q000188:drug therapy; D005767:Gastrointestinal Diseases / Q000188:drug therapy*; D005769:Gastrointestinal Motility / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000494:pharmacology / Q000627:therapeutic use*; D012602:Scopolamine Derivatives / Q000494:pharmacology / Q000627:therapeutic use*; D014287:Trimebutine / Q000627:therapeutic use*
D001565:Benzoates; D010276:Parasympatholytics; D012602:Scopolamine Derivatives; C016859:cimetropium; D014287:Trimebutine
Valutazione controllata di un nuovo spasmolitico di sintesi (DA 3177) nella patologia del tubo digerente di pertinenza chirurgica.